search for




 

A case of suspected rebound tumor progression after withdrawal of bevacizumab in patient with neurofibromatosis type 2
J Korean Skull Base Soc 2021;16(2):110-113
Published online September 30, 2021
© 2021 Korean Skull Base Society.

Shin Young Kim, Se A Lee, Jong Dae Lee

Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
Correspondence to: Jong Dae Lee
주소 : Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Wonmi-gu, Bucheon 14584, Korea
Tel : +82-32-621-5015
Fax : +82-32-621-5016
E-mail : ljdent@schmc.ac.krs.ac
Received August 21, 2021; Accepted September 15, 2021.
Abstract
Neurofibromatosis type 2 (NF2) is a rare hereditary disease characterized as bilateral vestibular schwannoma and other tumors of the brain or spinal nerve. There is no effective medical treatment for progressive NF2 other than surgical resection or radiation therapy. Recently, the anti-vascular endothelial growth factor (VEGF), bevacizumab, has been used for progressive vestibular schwannoma in NF2 patients to reduce tumor size and preserve hearing. However, there are some studies of rebound progression after withdrawal of bevacizumab. We report a case of a 24-year-old man with NF2 who was treated with bevacizumab. Bevacizumab was discontinued after 16 months of use. The patient was expired after six months.
Keywords : Neurofibromatosis type 2, Vestibular schwannoma, Bevacizumab


September 2021, 16 (2)
Full Text(PDF) Free

Social Network Service
Services

Cited By Articles
  • CrossRef (0)